###begin article-title 0
Association of dopaminergic pathway gene polymorphisms with chronic renal insufficiency among Asian Indians with type-2 diabetes
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Genetic markers conferring susceptibility to diabetes specific renal disease remains to be identified for early prediction and development of effective drugs and therapies. Inconsistent results obtained from analysis of genes from classical pathways generate need for examination of unconventional genetic markers having role in regulation of renal function. Experimental and clinical evidences suggest that dopamine is an important natriuretic hormone. Therefore, various genes involved in regulation of dopamine bioavailability could play a role in diabetic chronic renal insufficiency (CRI). We investigated the contribution of 12 polymorphisms from five Dopaminergic pathway genes to CRI among type-2 diabetic Asian Indian subjects.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 91 95 91 95 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD1</italic>
###xml 98 102 98 102 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2</italic>
###xml 104 108 104 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD3</italic>
###xml 110 114 110 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4</italic>
###xml 149 153 149 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT</italic>
Genetic association of 12 polymorphisms (SNPs) from five genes namely-dopamine receptor-1 (DRD1), DRD2, DRD3, DRD4, andcatechol-O-methyltransferase (COMT) with diabetic CRI was investigated using a case-control approach. Logistic regression analysis was carried out to correlate various clinical parameters with genotypes, and to study pair wise interactions between SNPs of different genes.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 5 28 5 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 ins/del C and G&gt;A </italic>
###xml 130 140 130 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 insC </italic>
###xml 153 168 153 168 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 insC/insC </italic>
###xml 171 186 171 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 ins/del C </italic>
###xml 216 220 216 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G&gt;A </italic>
###xml 314 328 314 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink">141 insC/delC </italic>
###xml 420 442 420 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">900 ins/del C in COMT </italic>
SNPs -141 ins/del C and G>A (1 kb upstream from exon 2) in DRD2 gene showed significant allelic and genotypic association. Allele -141 insC and genotype -141 insC/insC of -141 ins/del C polymorphism, and allele A of G>A SNP were found to be predisposing to CRI. Our result of allelic and genotypic association of -141 insC/delC SNP was also reflected in the haplotypic association. Heterozygous genotype of polymorphism 900 ins/del C in COMT gene was predisposing towards CRI.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 22 27 22 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 31 36 31 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
Some polymorphisms in DRD2 and COMT genes are significantly associated with susceptibility to CRI in the Asian Indian population which, if confirmed would be consistent with a suggested role of dopamine metabolism in disease occurrence.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
A large number of genetic association studies for unraveling the genetic basis of renal disease in diabetes have been carried out using polymorphisms in candidate genes from various postulated biochemical and metabolic pathways. These include renin-angiotensin-aldosterone system (RAAS), protein kinase C (PKC)-polyol, advanced glycation end (AGE) product, hexosamine and oxidative stress. However the results are confusing and identification of genetic susceptibility to chronic renal insufficiency (CRI) continues to be a challenge. This suggests the need for examining other unconventional genetic markers having role in regulation of normal physiological functions of kidney, especially under hyperglycemic condition.
###end p 11
###begin p 12
###xml 447 448 447 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 449 450 449 450 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 712 713 712 713 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 782 785 782 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1</italic>
###xml 828 832 828 832 <italic xmlns:xlink="http://www.w3.org/1999/xlink">AT1 </italic>
###xml 859 860 859 860 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 861 862 861 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 952 953 952 953 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1211 1212 1211 1212 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 1213 1214 1213 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 1335 1339 1335 1339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT</italic>
###xml 1520 1522 1520 1522 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1523 1525 1523 1525 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 899 903 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Dopamine is an important natriuretic hormone involved in the regulation of blood pressure, and salt-water reabsorption in kidney. While angiotensin II, another hormone involved in natriuresis, stimulates sodium reabsorption through activation of Na-K-ATPase and Na/H exchanger, dopamine acts antagonistically and inhibits reabsorption by inhibiting Na-K-ATPase and Na/H exchanger, regulating sodium transport and excretion in the proximal tubule [1-3]. Moreover, there are ample empirical evidences to support that dopamine through specific dopamine receptors influences various components of renin angiotensin aldosterone system (RAAS). While D1 like receptors stimulate renin release, D3 receptor inhibits it [4]. D3 receptor of dopamine decreases angiotensin II type 1 receptor (AT1) expression and angiotensin II binding to AT1 in renal proximal tubules [3,4]. Disruption of D3 receptor gene in mice induces a renin dependent form of hypertension [5]. Such interactions between dopamine and components of RAAS could modulate the potential effects of RAAS, which besides regulating vascular tone and Na ion balance in kidney also influences cytokine mediated inflammatory pathway in diabetic kidney disease [6-9]. In addition, administration of nitecapone, an inhibitor of dopamine metabolizing enzyme catechol-O-methyltransferase (COMT; EC 2.1.1.6), has been found to effectively abolish glomerular hypertension and reduce progression to glomerulosclerosis by inhibiting Na-K-ATPase in a dopamine dependent fashion [10,11]. These findings reiterate a potential role of dopaminergic pathway genes in conferring susceptibility to diabetic CRI through modulation of dopamine levels.
###end p 12
###begin p 13
###xml 152 154 152 154 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 294 296 294 296 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
Several polymorphisms in dopaminergic pathway genes have been identified and extensively investigated for their role in hypertension and schizophrenia [12-17]. There is only one report on association of D3 receptor of dopamine with diabetic nephropathy but in individuals with type-1 diabetes [18]. Due to significant role of genes from dopaminergic pathway in kidney function, in this pilot study, we investigated the susceptibility conferred by polymorphisms in dopaminergic pathway genes to CRI among individuals with type-2 diabetes, hitherto unexplored.
###end p 13
###begin title 14
Methods
###end title 14
###begin title 15
Subjects
###end title 15
###begin p 16
###xml 105 107 105 107 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 564 576 <span type="species:ncbi:9606">participants</span>
###xml 1378 1386 <span type="species:ncbi:9606">Patients</span>
Complete clinical and demographic characteristics of the study population have been previously reported [19]. Briefly, in this retrospective case-control analysis consecutive subjects suffering from type-2 diabetes with CRI (cases, CRI, n = 196), and diabetics without any evidence of diabetic kidney disease (controls, DM, n = 225) were recruited from the outpatient departments of the four participating medical institutions situated across India. The study was approved by respective institutional ethics committee and an informed consent obtained from all the participants. For CRI, the inclusion criteria were subjects with type 2 diabetes for >/=2 years, plus two or more of the following: serum creatinine >/=150 umol/l, urinary albumin excretion rate (UAER) > 200 mg/l, and presence of retinopathy. Retinopathy was diagnosed by either fundoscopic examination or fluoroangiographic study. 10 ml venous blood was collected from each individual included in the study for biochemical and genetic analysis. Biochemical analyses to determine fasting glucose, glycated hemoglobin, serum creatinine, triglycerides, total cholesterol, and albumin were carried out at the respective centres using automated analyzers. Using serum creatinine as a surrogate marker we calculated glomerular filtration rate (GFR) by using the online modified diet in renal disease (MDRD) calculator. Patients with drug induced nephrotoxic damage or secondary causes of albuminuria such as obstructive renal disease, renal stone disease and acute urinary tract infection were excluded from this group. Normoalbuminuric (AER < 20 mg/l) type-2 diabetes subjects of >/= 10 years duration of diabetes (mean duration 17.07 +/- 6.69 years) were recruited as control diabetes subjects. Normoalbuminuria among control (DM) subjects was determined by timed urine collections. An aliquot of blood from the four centres was transported to the genetics laboratory for DNA isolation. DNA was isolated from the lymphocytes using the conventional phenol-chloroform organic extraction method and used for genetic analysis.
###end p 16
###begin title 17
Genetic analysis
###end title 17
###begin p 18
A total of 12 polymorphisms from five candidate genes were genotyped in DM (controls) and CRI (cases) subjects. These include:
###end p 18
###begin p 19
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 0 24 0 24 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>COMT </italic>(+116790; 22q11.21)</bold>
###xml 26 35 26 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-287 A&gt;G </italic>
###xml 48 50 48 50 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 53 60 53 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">408 C&gt;G</italic>
###xml 63 65 63 65 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 66 92 66 92 <italic xmlns:xlink="http://www.w3.org/1999/xlink">and 472 G&gt;A (Val 158 Met) </italic>
###xml 93 95 93 95 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 111 125 111 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">900 ins/del C </italic>
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
COMT (+116790; 22q11.21): -287 A>G in promoter [14]; 408 C>G) [20]and 472 G>A (Val 158 Met) [14] in exon 4 and 900 ins/del C in 3'UTR [15];
###end p 19
###begin p 20
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD1 </italic>
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DRD1 </italic>(*126449; 5q35.2)</bold>
###xml 24 32 24 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-48 A&gt;G </italic>
###xml 51 57 51 57 <bold xmlns:xlink="http://www.w3.org/1999/xlink">rs4532</bold>
###xml 60 61 60 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
DRD1 (*126449; 5q35.2): -48 A>G (5'UTR of exon 2) (rs4532) [2];
###end p 20
###begin p 21
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DRD2 </italic>(*126450; 11q23.2)</bold>
###xml 25 40 25 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 ins/del C </italic>
###xml 41 50 41 50 <bold xmlns:xlink="http://www.w3.org/1999/xlink">rs1799732</bold>
###xml 51 84 51 84 <italic xmlns:xlink="http://www.w3.org/1999/xlink">; G&gt;A, 1 kb upstream from exon 2 </italic>
###xml 98 100 98 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 101 103 101 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 110 144 110 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T&gt;C, 10 kb downstream from exon 8 </italic>
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
DRD2 (*126450; 11q23.2): -141 ins/del C (rs1799732); G>A, 1 kb upstream from exon 2 (rs17294542) [21,22]; and T>C, 10 kb downstream from exon 8 (rs1800497) [21,22];
###end p 21
###begin p 22
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD3 </italic>
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DRD3 </italic>(*126451; 3q13.31)</bold>
###xml 33 47 33 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">C&gt;T (ser9Gly) </italic>
###xml 58 60 58 60 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
DRD3 (*126451; 3q13.31): -rs6280 C>T (ser9Gly) in exon 2 [16];
###end p 22
###begin p 23
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
###xml 0 23 0 23 <bold xmlns:xlink="http://www.w3.org/1999/xlink"><italic>DRD4 </italic>(*126452; 11p15.5)</bold>
###xml 26 44 26 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">120 bp duplication</italic>
###xml 85 87 85 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 90 99 90 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-521 C&gt;T </italic>
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 131 133 131 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
DRD4 (*126452; 11p15.5): -120 bp duplication, 1.2 kb upstream from initiation codon [23], -521 C>T [17]; and 48 bp VNTR in exon 3 [24].
###end p 23
###begin p 24
###xml 314 315 314 315 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Genotyping was done using either polymerase chain reaction (PCR)-restriction fragment length polymorphisms (RFLP) or PCR-length polymorphism (LP) approach following the method described in the respective quoted references. Genotypic profiles obtained for each of the polymorphisms are presented in Additional file 1. The digested PCR products were resolved on 2-3% agarose gel stained with ethidium bromide.
###end p 24
###begin title 25
Statistical Analysis
###end title 25
###begin p 26
###xml 88 90 86 88 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 449 451 445 447 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 597 599 593 595 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 600 602 596 598 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 683 685 679 681 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 686 688 682 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
Comparison of all clinical variables between DM and CRI subjects were carried out by chi2 test for nominal variables or t-test for continuous variables. Continuous variables where skewed distribution was observed were compared by Mann Whitney U test and values are reported as mean and range. Hardy-Weinberg equilibrium (HWE) was tested for each of the genetic marker. Allelic and genotypic associations of SNPs/VNTRs were evaluated by Pearson's chi2 test followed by odds ratio and 95% CI computation. Power of the sample size for each of the SNPs was calculated using PAWE software version 1.2 [25,26]. Haplotype analysis was performed using PHASE-standard analysis version 2.0.2 [27,28]. Chi-square values were derived from a series of 2 x 2 contingency tables based on the frequency of each haplotype versus all others between the DM and the CRI groups. Linear and logistic regression analyses were carried out to correlate various clinical parameters with genotypes and to study pair wise interactions between SNPs of different genes. P values < 0.05 were subject to Bonferroni's correction.
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Clinical analysis
###end title 28
###begin p 29
###xml 74 75 74 75 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 36 43 <span type="species:ncbi:9606">patient</span>
Clinical characteristics of the two patient groups are presented in Table 1.
###end p 29
###begin p 30
Clinical characteristics of the study population
###end p 30
###begin p 31
###xml 52 53 50 51 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 104 106 102 104 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b </sup>
###xml 147 149 145 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c </sup>
###xml 167 169 165 167 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d </sup>
###xml 182 184 178 180 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 190 192 186 188 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e </sup>
Data presented as mean +/- SD (* median and range). atype-2 diabetes subjects without nephropathy (DM); b with diabetic renal insufficiency (CRI); c Student's t test; d Pearson's chi2 test; e Mann-Whitney U test.
###end p 31
###begin title 32
Genetic analysis: Efficiency of PCR based genotyping was approximately 98% with at least two additional attempts for genotyping of failed samples
###end title 32
###begin title 33
COMT
###end title 33
###begin p 34
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 136 150 136 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">900 ins/del C </italic>
###xml 330 331 330 331 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
No allelic association of any of the four SNPs in this gene with diabetic CRI was observed (Table 2). Only the heterozygote genotype of 900 ins/del C SNP was significantly associated with CRI (P = 0.018, OR 1.66, 95%CI 1.09-2.52). Haplotypes generated using genotypic profiles of the four SNPs in COMT gene are presented in Table 3. We observed significant association of three haplotypes in COMT gene, which were retained even after Bonferroni's correction.
###end p 34
###begin p 35
Allele and genotype frequencies of SNPs in COMT, DRD1, DRD2, DRD3 and DRD4 genes and their association status with diabetic CRI.
###end p 35
###begin p 36
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aSignificant after Bonferroni's correction alpha = 0.0042
###end p 36
###begin p 37
SNP haplotypes in COMT gene
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aOrder of SNPs in the COMT haplotypes: -287 A>G, 408 C>G, 472 G > A and 900 Ins/Del C
###end p 38
###begin p 39
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bSignificant after Bonferroni's correction alpha = 0.0035
###end p 39
###begin p 40
*n = total number
###end p 40
###begin p 41
**f = frequency
###end p 41
###begin title 42
DRD1
###end title 42
###begin p 43
###xml 107 108 107 108 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
No allelic or genotypic association of the -48 A>G polymorphism with CRI in our sample set was seen (Table 2).
###end p 43
###begin title 44
DRD2
###end title 44
###begin p 45
###xml 121 143 121 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">141 ins/del C and G&gt;A </italic>
###xml 177 181 177 181 <italic xmlns:xlink="http://www.w3.org/1999/xlink">T&gt;C </italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
Of the three polymorphisms analysed in this gene, we observed a highly significant allelic and genotypic association of -141 ins/del C and G>A (1 kb upstream from exon 2) SNPs. T>C (10 kb downstream from exon 8) SNP did not show any allelic or genotypic association with diabetic kidney disease (Table 2). Out of the eight possible haplotypes in our sample set, three (-141 insC-A-T, -141 insC-A-C, and -141 delC-A-C) were significantly associated with CRI (Table 4).
###end p 45
###begin p 46
SNP haplotypes in DRD2 gene
###end p 46
###begin p 47
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aOrder of SNPs in the DRD2 haplotypes: -141 ins/del C - G>A (Intron 1) - T>C (Intron 7)
###end p 47
###begin p 48
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bSignificant after Bonferroni's correction alpha = 0.0063
###end p 48
###begin p 49
*n = total number
###end p 49
###begin p 50
**f = frequency
###end p 50
###begin title 51
DRD3
###end title 51
###begin p 52
###xml 70 78 70 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Ser9Gly </italic>
###xml 125 126 125 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
No allelic or genotypic association of the most commonly investigated Ser9Gly SNP with CRI was observed in this study (Table 2).
###end p 52
###begin title 53
DRD4
###end title 53
###begin p 54
###xml 388 389 388 389 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
None of the three polymorphisms tested in the gene showed significant genotypic or allelic association with CRI. Out of 21 possible haplotypes in our case-control population, only haplotype 2-1-3 [(-120) no duplication - (-521) C - VNTR 467] was found to be marginally associated with CRI. However, after Bonferroni's correction the haplotype did not retain significance (Additional file 2).
###end p 54
###begin p 55
###xml 329 333 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G&gt;A </italic>
###xml 591 615 591 615 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 ins/del C, and G&gt;A </italic>
###xml 659 664 659 664 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
Multivariate logistic regression analysis was carried out using disease status as a dependent variable, and age, gender, BMI, duration of diabetes, creatinine clearance rate and genotypes of all 12 polymorphisms as independent variables. A significant association of SNPs -141 ins/del C (P = 0.000; OR 2.85, 95%CI 1.73-4.74) and G>A (1 kb upstream from exon 2) (P = 0.006; OR 1.84, 95%CI 1.19-2.84) in DRD2 gene with CRI was observed. Further categorical analysis identified genotypes -141 ins/ins C (P = 0.015; OR 3.35, 95%CI 1.27-8.84) and AA (P = 0.013; OR 1.88, 95%CI 1.14-3.10) of SNPs -141 ins/del C, and G>A (1 kb upstream from exon 2) respectively of DRD2 gene to be predisposing to CRI. Pair-wise interactions between different polymorphisms included in this study were tested using multiple logistic regression analysis. No significant interaction between any of these polymorphisms/genes was observed.
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 213 215 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 761 763 761 763 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 889 891 889 891 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 883 887 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
In addition to its classical role as a neurotransmitter, dopamine also acts as a natriuretic hormone that has implications in kidney function. Dopamine down regulation causes Na retention and renal tissue injury [11]. In addition dopamine also modulates the activity and availability of Ang II, the key molecule of renin-angiotensin-aldosterone system in kidney. An altered interplay of dopamine and Ang II could disturb the vascular tone, sodium ion balance, and enhance cytokine-mediated injury to renal tissue. Thus, as mentioned earlier, genetic variations in genes controlling the bio-availability of dopamine could be pathological. While various studies have implicated genetic variations in COMT and dopamine receptor genes in essential hypertension [29-35], and one study has implicated COMT (based on a functional assay using a COMT inhibitor) in diabetic kidney disease in rats [10], an association of dopaminergic pathway gene polymorphisms with kidney disease among individuals with type-2 diabetes has not been tested in any population so far. This is the first report on the role of multiple SNPs in dopaminergic pathway genes conferring susceptibility to diabetic CRI.
###end p 57
###begin p 58
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 42 56 42 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink">900 ins/del C </italic>
###xml 115 116 115 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 124 134 124 134 <italic xmlns:xlink="http://www.w3.org/1999/xlink">insC/delC </italic>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 710 712 710 712 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 788 789 788 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1436 1441 1436 1441 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
###xml 1502 1503 1502 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Out of four SNPs tested in COMT gene only 900 ins/del C showed a strong trend towards genotypic association (Table 2), with insC/delC genotype being predisposing (OR 1.66, CI 1.09-2.52) towards CRI. However, in the absence of any evidence for the functional status of this polymorphism at present, it would be difficult to substantiate its role in CRI. Val158Met polymorphism has been the most widely implicated for the activity status of COMT. Presence of methionine instead of valine in the protein makes it heat-labile and leads to fourfold reduction in activity [36]. In addition, different studies indicate that this functional polymorphism accounts for most of the variation in peripheral COMT activity [37]. Though, there was no allelic or genotypic association of this SNP (Table 2) in our study, in haplotypic combinations this polymorphism seems to be important. Haplotype 1-1-2-2 [A-C-A (Met)-del C] is predisposing and haplotype 1-1-1-2 [A-C-A (Val)-del C], with only one allele different at Val158Met locus, is protective to CRI. 158Val, the high activity allele of the enzyme, is the predominant allele in our population and is required for regulating normal physiological levels of dopamine. Replacement of Val allele by Met in the haplotype may increase dopamine levels, which is an antagonist to Ang II, and may alter vascular tone and sodium ion balance in kidney. The only other significantly associated haplotype in COMT gene, 2-1-2-1 (G-C-A-InsC), is protective towards CRI (Table 3). In the absence of any information on functional status of the other three polymorphisms in this gene, it seems difficult to assess the protective nature of this haplotype.
###end p 58
###begin p 59
###xml 78 101 78 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 ins/del C and G&gt;A </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2 </italic>
###xml 203 204 203 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 519 520 519 520 <bold xmlns:xlink="http://www.w3.org/1999/xlink">-</bold>
###xml 833 849 833 849 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 insC/del C </italic>
###xml 1094 1095 1094 1095 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1240 1242 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
Out of eight polymorphisms in four dopamine receptor genes (D1-D4), only SNPs -141 ins/del C and G>A (1 kb upstream from exon 2) in DRD2 gene, showed significant allelic and genotypic association (Table 2), with satisfactory power of the sample size [G = 53% for -141 ins/del C; G = 50.6% for G>A (1 kb upstream from exon 2)]. Odds ratio calculation identified -141 insC allele (OR 2.01, CI 1.35-3.00) and insC/insC genotype (OR 2.19, CI 1.37-3.50) to be predisposing, and insC/delC genotype (OR 0.53, CI 0.33-0.87) of -141 ins/del C SNP to be protective to diabetic CRI. Allele 'A' (OR 1.68, CI 1.17-2.42) was found to be predisposing and allele 'G' (OR 0.59, CI 0.41-0.85), and genotype 'GG' (OR 0.52, CI 0.32-0.82) of G>A (1 kb upstream from exon 2) SNP to be protective to CRI. Our result of allelic and genotypic association of -141 insC/del C SNP was also reflected in the haplotypic results. The predisposing haplotypes, 1-2-1 (-141 insC-A-T) and 1-2-2 (-141 insC-A-C), contained -141 insC allele and the protective haplotype, 2-2-2 (-141 delC-A-C) contained the -141 delC allele (Table 4). Based on functional analysis it has been reported that -141 delC allele has decreased promoter strength as compared to the -141 ins C allele [38]. Considering the above mentioned facts, it could be argued that -141 ins C allele may lead to excess bio-availability of dopamine, which may alter vascular tone and sodium ion balance in kidney. Function of G>A SNP (I Kb upstream from exon 2) in the gene is not known and thus it's difficult to comment on our observation on this SNP.
###end p 59
###begin p 60
###xml 487 495 487 495 <italic xmlns:xlink="http://www.w3.org/1999/xlink">apriori </italic>
###xml 1067 1069 1067 1069 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 1372 1374 1372 1374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
There are a few study limitations. Present study is a candidate gene based case-control study and most candidate gene case-control studies of complex traits to date have been disappointing. In diabetic nephropathy alone, many initial reports of significant associations have not withstood the test of replication in other cohorts. Such inconsistencies stem primarily from the very low pre-test probability that any given gene contributes to the susceptibility of a complex trait despite apriori hypotheses based on cell, tissue, or animal model experiments. Other reasons include the use of underpowered sample sizes, multiple testing, phenotypic heterogeneity, poor phenotype characterization, selection bias, population stratification, and incomplete knowledge of the complete set of allelic variants in the region of a candidate gene. Our study involves a small sample size. Harrington has commented on standards of evidence in the genomic age and suggests that in a case control study the sample size should be >1000 subjects to arrive at worthwhile conclusions [39]. However, only a very few investigators have access to such a large data and inspite of being a multi-site study the present study could not achieve such large numbers. On the other hand the present study fulfils most of the criteria of a good genetic association study suggested by Hattersley et al [40]. The diagnosis of diabetic renal disease in the present study is based on multiple criteria. Diabetes can produce a large variety of renal lesions and it is likely that molecular and genetic pathways involved in each of these are different. This is the first investigation of association of polymorphisms in the dopaminergic pathway genes with CRI. Significant allelic, genotypic, and haplotypic associations observed with diabetic CRI in this study seem interesting but extrapolation of the results demands replication in a larger sample set.
###end p 60
###begin title 61
Conclusion
###end title 61
###begin p 62
###xml 35 50 35 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">-141 ins/del C </italic>
###xml 54 58 54 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">G&gt;A </italic>
###xml 89 93 89 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2</italic>
###xml 99 113 99 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">900 ins/del C </italic>
###xml 116 121 116 121 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT </italic>
It is concluded that polymorphisms -141 ins/del C and G>A (1 kb upstream from exon 2) in DRD2, and 900 ins/del C in COMT genes are associated with susceptibility to diabetic CRI, which if confirmed by replication studies and/or expression analysis would be consistent with a role of dopamine metabolism in disease occurrence. Given that some of the genetic variants were associated with susceptibility and others with protection could be an important indication of the mechanisms of CRI itself. The use of the apposite polymorphisms for prediction or prognosis could well be a subordinate step to that of the confirmation of the observation and of understanding the disease itself.
###end p 62
###begin title 63
Abbreviations
###end title 63
###begin p 64
CRI: Chronic renal insufficiency; DM: type-2 diabetes; OR: Odds ratio.
###end p 64
###begin title 65
Competing interests
###end title 65
###begin p 66
The author(s) declare that they have no competing interests.
###end p 66
###begin title 67
Authors' contributions
###end title 67
###begin p 68
PP was involved in the study design, carried out molecular genetics and statistical analyses, compiled the data, wrote the Ms.; KMPK, ACA, AG, and RG were the principal clinical investigators involved in study design, defining exclusion and inclusion criteria of study subjects and were mainly responsible for identification of study subjects from their respective clinical centres; BKT was the principal geneticist and co-ordinator of the project, involved in conceptualization of the project, study design, oversee complete genetic analyses in the laboratory, critical inputs and finalization of the manuscript.
###end p 68
###begin title 69
Supplementary Material
###end title 69
###begin title 70
Additional file 1
###end title 70
###begin p 71
###xml 16 17 16 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 27 31 27 31 <italic xmlns:xlink="http://www.w3.org/1999/xlink">COMT</italic>
###xml 33 37 33 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD1</italic>
###xml 39 43 39 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD2</italic>
###xml 45 50 45 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD3 </italic>
###xml 54 59 54 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">DRD4 </italic>
Additional file 1. SNPs in COMT, DRD1, DRD2, DRD3 and DRD4 genes, their location, primer sequences, PCR conditions and restriction enzyme with product sizes.
###end p 71
###begin p 72
Click here for file
###end p 72
###begin title 73
Additional file 2
###end title 73
###begin p 74
###xml 16 17 16 17 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S2">2</xref>
Additional file 2. SNP haplotypes in DRD4 gene.
###end p 74
###begin p 75
Click here for file
###end p 75
###begin title 76
Acknowledgements
###end title 76
###begin p 77
Financial assistance through senior research fellowships to Pushplata Prasad, from Council of Scientific and Industrial Research, New Delhi.
###end p 77
###begin article-title 78
Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR
###end article-title 78
###begin article-title 79
Dopamine D1 receptor gene polymorphism is associated with essential hypertension
###end article-title 79
###begin article-title 80
###xml 87 91 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats
###end article-title 80
###begin article-title 81
Ser9Gly polymorphism in the dopamine D3 receptor gene is not associated with essential hypertension in the Japanese
###end article-title 81
###begin article-title 82
Disruption of the dopamine D3 receptor gene produces renin-dependent hypertension
###end article-title 82
###begin article-title 83
###xml 23 28 <span type="species:ncbi:9606">human</span>
Angiotensin II induces human TGF-beta 1 promoter activation: similarity to hyperglycaemia
###end article-title 83
###begin article-title 84
PKC and high glucose stimulate collagen alpha 1 (IV) transcriptional activity in a reporter mesangial cell line
###end article-title 84
###begin article-title 85
###xml 198 202 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Characterization of protein kinase C beta isoform activation on the gene expression of transforming growth factor-beta, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats
###end article-title 85
###begin article-title 86
RANTES promoter genotype is associated with diabetic nephropathy in type 2 diabetic subjects
###end article-title 86
###begin article-title 87
Inhibition of COMT induces dopamine-dependent natriuresis and inhibition of proximal tubule Na-K-ATPase
###end article-title 87
###begin article-title 88
###xml 91 95 <span type="species:ncbi:10118|species:ncbi:10116">rats</span>
Combined antioxidant and COMT inhibitor treatment reverses renal abnormalities in diabetic rats
###end article-title 88
###begin article-title 89
Genome-wide scan of predisposing loci for increased diastolic blood pressure in Finnish siblings
###end article-title 89
###begin article-title 90
Genomewide linkages scan of resting blood pressure: HERITAGE Family Study. Health, Risk Factors, Exercise Training, and Genetics
###end article-title 90
###begin article-title 91
Schizophrenia and fuctional polymorphism in the MAO and COMT genes: No evidence for association or epistasis
###end article-title 91
###begin article-title 92
Identification of sequence variants and analysis of the role of the Catechol - O - methyltransferase gene in schizophrenia susceptibility
###end article-title 92
###begin article-title 93
Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia
###end article-title 93
###begin article-title 94
A genetic polymorphism in the promoter region of DRD4 associated with expression and schizophrenia
###end article-title 94
###begin article-title 95
###xml 91 99 <span type="species:ncbi:9606">patients</span>
Dopamine D3 receptor gene polymorphisms, blood pressure and nephropathy in type 1 diabetic patients
###end article-title 95
###begin article-title 96
Chronic renal insufficiency in individuals with type 2 diabetes and role of RAAS gene polymorphisms
###end article-title 96
###begin article-title 97
National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification
###end article-title 97
###begin article-title 98
###xml 29 34 <span type="species:ncbi:9606">human</span>
A structural polymorphism of human dopamine D2 receptor, D2(Ser311-->Cys)
###end article-title 98
###begin article-title 99
PCR detection of the TaqA RFLP at the DRD2 locus
###end article-title 99
###begin article-title 100
Tandem duplication polymorphism upstream of the dopamine D4 receptor gene (DRD4)
###end article-title 100
###begin article-title 101
###xml 26 31 <span type="species:ncbi:9606">human</span>
Cloning of the gene for a human dopamine D4 receptor with high affinity for the antipsychotic clozapine
###end article-title 101
###begin article-title 102
Power and sample size calculations for case-control genetic association tests when errors present: application to single nucleotide polymorphisms
###end article-title 102
###begin article-title 103
Errors and linkage disequilibrium interact multiplicatively when computing sample sizes for genetic case-control association studies
###end article-title 103
###begin article-title 104
A new statistical method for haplotype reconstruction from population data
###end article-title 104
###begin article-title 105
Comparison of bayesian methods for haplotype reconstruction from population genotype data
###end article-title 105
###begin article-title 106
Renal dopamine and sodium homeostasis
###end article-title 106
###begin article-title 107
Dopamine and the kidney: a role in hypertension?
###end article-title 107
###begin article-title 108
Regulation of blood pressure by dopamine receptors
###end article-title 108
###begin article-title 109
Ethnic origin determines the impact of genetic variants in dopamine receptor gene (DRD1) concerning essential hypertension
###end article-title 109
###begin article-title 110
Association between a dopamine-4 receptor polymorphism and blood pressure
###end article-title 110
###begin article-title 111
Single-nucleotide polymorphisms for diagnosis of salt-sensitive hypertension
###end article-title 111
###begin article-title 112
Patterns of genetic variation in the hypertension candidate gene GRK4: ethnic variation and haplotype structure
###end article-title 112
###begin article-title 113
Catechol-O-methyltransferase (COMT) biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors
###end article-title 113
###begin article-title 114
Effect of COMT val(108/158)met genotype on frontal lobe function and risk for schizophrenia
###end article-title 114
###begin article-title 115
A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia
###end article-title 115
###begin article-title 116
Eliminating the improbable: Sherlock Holmes and standards of evidence in the genomic age
###end article-title 116
###begin article-title 117
What makes a good genetic association study?
###end article-title 117

